Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) provide detailed insight into the company’s biotechnology business, capital structure and diagnostic platform for early lung cancer detection. Registration statements on Form S-1 and Form S-3, along with related amendments, describe offerings of common stock, Series B Convertible Preferred Stock and multiple series of warrants to purchase common stock, including their terms, exercise prices, anti-dilution provisions and resale registration arrangements for selling stockholders.
Through periodic reports and current reports on Form 8-K, bioAffinity discloses operating and financial information related to CyPath® Lung and its subsidiary Precision Pathology Laboratory Services (PPLS). These filings discuss revenue from CyPath® Lung testing and pathology services, research and clinical development expenses, and strategic decisions such as discontinuing certain unprofitable pathology services to focus resources on commercialization of the CyPath® Lung test.
Filings also document corporate actions and listing matters, including a one-for-thirty reverse stock split approved and implemented to address Nasdaq minimum bid price requirements, and subsequent confirmation that the company regained compliance with Nasdaq continued listing standards. Investors reviewing BIAFW often use these documents to understand how changes in capital structure, such as new warrant issuances or amendments to floor prices, affect potential dilution and warrant economics.
bioAffinity’s SEC disclosures further outline its intellectual property position, describing patents that protect the AI-built algorithm and flow cytometry platform used in CyPath® Lung and other diagnostics in development. While the full text of annual reports (Form 10-K) and quarterly reports (Form 10-Q) is not reproduced here, those filings typically provide comprehensive risk factor discussions, management’s analysis of operations and liquidity, and additional detail on the company’s biotechnology programs.
On Stock Titan’s filings page, users can access real-time updates from EDGAR, including 8-K current reports on material events, registration statements related to equity financings and warrants, and periodic reports. AI-powered summaries help explain key elements of complex filings, highlight changes in capital structure, and surface information relevant to BIAFW warrant holders and equity investors, such as reverse stock split terms, warrant adjustments and use of proceeds from offerings.
bioAffinity Technologies, Inc. (symbol BIAFW) has submitted a post-effective amendment on Form POS AM. The excerpt provided is almost entirely made up of XBRL tag references that map the company’s equity classes, incentive plans, warrants and other membership interests across various reporting periods. No narrative discussion, transaction description, or quantitative financial statements accompany the tags. As presented, the amendment appears to be an administrative update to existing registration statements—likely refreshing or re-labeling warrant-related securities—rather than announcing new capital raises or operational developments.
Because the filing lacks earnings data, cash-flow details, or material corporate actions, it offers no immediate insight into profitability, liquidity, or strategy. For investors, the document’s impact is therefore minimal unless later supplemented by a prospectus or pricing information that changes dilution expectations.
bioAffinity Technologies has filed a POS AM (Post-Effective Amendment) related to their warrant securities (BIAFW). The filing includes several key warrant-related developments:
- Multiple Warrant Offerings: The company has various warrant classes including tradeable and non-tradeable warrants, pre-IPO convertible notes, and placement agent warrants
- Recent Warrant Activity: Notable warrant transactions occurred in March 2024, August 2024, and October 2024, with additional warrant inducement events in February 2025
- Equity Incentive Plans: The company maintains both 2014 and 2024 equity incentive plans, including restricted stock units (RSUs) and stock options for employees, non-employees, and board members
- Financial Structure: The filing details the company's capital structure including common stock, preferred stock, and various warrant classifications with their respective terms and conditions
This amendment appears to update and clarify the terms and conditions of the company's outstanding warrants and related securities, ensuring compliance with SEC regulations and providing updated information to investors.